Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AFM13 |
Synonyms | |
Therapy Description |
AFM13 is a bispecific antibody against human CD30 and CD16A, which cross-links tumor cells and NK cells, resulting in anti-tumor immune response (PMID: 26231785). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AFM13 | AFM13 is a bispecific antibody against human CD30 and CD16A, which cross-links tumor cells and NK cells, resulting in anti-tumor immune response (PMID: 26231785). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04101331 | Phase II | AFM13 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT03192202 | Phase Ib/II | AFM13 | AFM13 in Relapsed/Refractory Cutaneous Lymphomas | Completed | USA | 0 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Recruiting | USA | 0 |